Japan's Eisai to buy U.S. MGI Pharma for $3.9 bln
|
|
|
TOKYO (Reuters) - Drugmaker Eisai Co Ltd <4523.T> said on Monday it would buy U.S. biopharmaceutical firm MGI Pharma Inc for $3.9 billion cash to help it expand in the United States and strengthen its pipeline in cancer treatments.The planned purchase of the cancer specialist is the latest example of accelerating M&A in the biotechnology sector, which has seen a scramble by drugmakers to secure promising technologies and pipelines developed by small biotech firms.Eisai will offer $41 per share, in a bid approved by MGI, which represents a 38.7 percent premium to MGI's closing share price on November 28, the last business day prior to MGI's announcement it was exploring strategic alternatives.It said it would finance the deal with its own cash and through bank loans.MGI's products include Aloxi, a treatment to prevent chemotherapy-induced nausea; Gliadel Wafer, a drug delivery device in the treatment of brain cancer; and Dacogen, a treatment for a group of blood disorders known as myelodysplastic syndromes that often precedes leukemia.Big-ticket biotech deals this year include AstraZeneca buying MedImmune for $15.6 billion and Celgene acquiring Pharmion , a rival of MGI, for $2.9 billion. U.S. biotech group Biogen is also on the block.(Reporting by Edwina Gibbs)
(c) Reuters 2007. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
|
|
|
|
|
|
Related News
US economists: 'Jobless' recovery to reach bottom at start of 2010
Washington - The US economy will start adding jobs some time in the first quarter of 2010, ending a so-called jobless recovery that has plagued the world's largest economy since the summer months, according to a survey released Monday. But the Nati...
Hershey, Nestle, sweeten war for Cadbury
Washington - Hershey and Nestle are expected to jump into the war over Cadbury sweets, media reports said Saturday, just weeks after the British-based stalwart rejected a hostile bid by US Kraft Inc. The growing market for chocolate in the developing...
US stock drop slightly on Dell profits, mixed for week
New York - Technology and energy shares pushed US stocks lower Friday, capping a mixed week for investors amid unease about the pace of the world's economic recovery. Tech stocks slid after a disappointing earnings report from computer giant Dell, wh...
GM: Opel restructuring plan by mid-December; cuts up to 25 per cent
Washington - US carmaker General Motors will present a new restructuring plan for its European operations by mid-December, Nick Reilly, the new head of GM Europe, wrote on his new blog Friday. While the details were still being hashed out, Reilly war...
US stock sell-off on fears of weak recovery
New York - US stocks followed global markets in a broad decline amid investor fears over the world's uneasy recovery from recession. Major US stock indices fell about 1 per cent on average, following hefty declines in the DJ Euro Stoxx 50 and Japan's...
US leading economic indicator gains 0.3 per cent
Washington - A key measure of US economic performance gained in October, according to a private research group Thursday, signalling that a broader recovery may be taking hold. The New York-based Conference Board's Leading Economic Index added 0.3 per...
US stocks fall slightly on technology earnings
New York - US stocks posted modest losses Wednesday on poor profit forecasts from technology firms and a surprising dip in home construction. Earnings from Salesforce.com and Autodesk were worse than expected. Other technology shares losing ground in...
|
|
|
|
|
|
|
|
